|
WO2021077162A1
|
|
Modulation of cellular viability
|
|
WO2021056071A1
|
|
Treatment of dementia
|
|
WO2021056072A1
|
|
Treatment of excitotoxicity-related conditions
|
|
WO2021056064A1
|
|
Treatment of tauopathies
|
|
WO2021026601A1
|
|
Compositions and methods for treatment
|
|
WO2020257861A1
|
|
Diagnosis and monitoring of neurodegenerative diseases
|
|
WO2020243792A1
|
|
Recombinant yeast
|
|
WO2020154770A1
|
|
Complexes and compositions comprising probucol and uses thereof
|
|
WO2020000028A1
|
|
Systems and methods for obtaining auditory evoked potentials
|
|
AU2019201584B1
|
|
Immunosuppressive glycoforms of soluble cd52
|
|
WO2019113638A1
|
|
Retractor
|
|
WO2019090392A1
|
|
Device, method and system for optical imaging
|
|
WO2019046882A1
|
|
Gaseous mercury capture
|
|
WO2019033171A1
|
|
Cell culture substrates
|
|
WO2018170555A1
|
|
Improvements in terahertz lasers and terahertz extraction
|
|
AU2018212933A1
|
|
A patient-specific remote ischemic preconditioning system with multi- layer feedback control unit
|
|
WO2018132871A1
|
|
Method of producing chemicals in yeast
|
|
EP3566268A1
|
|
Single longitudinal mode ring raman laser
|
|
EP3535403A1
|
|
Modulation of protein accumulation and uses therefor
|
|
AU2017351742A1
|
|
Direction of arrival estimation
|
